Sarcoma
Treatment Market, by Sarcoma Type (Soft Tissue Sarcoma, Bone Sarcoma, and
Others), by Treatment Type (Chemotherapy, Targeted Therapy and Others), by
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online
Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific,
Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019
- 2027
Sarcoma is a type of cancer,
which occurs in connective tissues. Moreover, sarcoma is broadly classified
into two types such as soft tissue sarcoma and bone sarcoma. Soft tissue
sarcomas occur in tissues of blood vessels, nerves, tendons, muscles, fat, and
lining of the joints. Soft tissue sarcomas are mostly found in legs, arms,
abdomen, and chest. There are over 50 types of soft tissue sarcoma. Soft tissue
sarcoma symptoms include lump growth, abdominal pain, blood in stools, and vomiting.
Bone sarcomas mostly occur in the
long bones in arms and legs, and the pelvic bones. Symptoms of bone sarcoma
include fatigue, weaken bone leading to frequent fractures, bone pain, and
swelling and tenderness near the affected area. On the basis of severity of
cancer, sarcomas are divided into four stages, which include Stage 1 to Stage
4. Sarcomas are treated through chemotherapies, radiation therapies, targeted
therapies, and surgeries.
* The sample copy includes: Report Summary, Table of Contents,
Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/3537
Global Sarcoma Treatment Market –
Dynamics
Key players are focusing on
enhancing their product portfolio through product launches and new product
approvals for sarcoma treatment, which is expected to boost sarcoma treatment
market growth over the forecast period. For instance, in January 2020, Epizyme,
Inc., received the U.S. Food and Drug Administration (FDA) approval for
Tazverik, a target specific drug indicated for the treatment of epithelioid
sarcoma in patients of age 16 and above.
Furthermore, players operating in
the market are focused on research for development of new and efficient
treatment for sarcoma, which is expected to propel growth of the market over
the forecast period. For instance, in October 2019, Tyme Technologies, Inc.
initiated HopES, a phase 2 clinical trial, to evaluate safety and efficacy of
SM-88, a monotherapy for clinically advanced sarcomas. The trial is expected to
complete in the year 2022.
Global Sarcoma Treatment Market –
Regional Insights
North America accounted for the
largest market share in 2018. This is attributed to rising incidences of
sarcomas in the region. For instance, the American Cancer Society has estimated
that in 2020, around 13,130 new cases of soft tissue sarcomas will be diagnosed
in the U.S. Furthermore, in 2018, the American Cancer Society reported that
rhabdomyosarcoma accounts for around 3% cases of pediatric cancers in the U.S.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/sarcoma-treatment-market-3537
Europe is expected to be the
second-largest market in global sarcoma treatment market and it is expected to
witness significant growth over the forecast period, owing to increasing number
of sarcoma incidences in the region. For instance, in July 2018, Sarcoma UK, a
national cancer charity, reported that over 5,300 cases of sarcomas are
diagnosed every year in the U.K.
Global Sarcoma Treatment Market –
Competitive Landscape
Key players operating in the
sarcoma treatment market include Novartis International AG, Eli Lilly and
Company, Amgen Inc., Johnson & Johnson, Johnson & Johnson, Bayer AG,
Epizyme, Inc., Tyme Technologies, Inc., and others.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/3537
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment